|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
NCCN Practice Guidelines in Oncology.
Uterine Neoplasms Version 1.2013. 2013, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#uterine.
|
|
3
|
Cheng H, Liu P, Zhang F, et al: A genetic
mouse model of invasive endometrial cancer driven by concurrent
loss of Pten and Lkb1 is highly responsive to mTOR inhibition.
Cancer Res. 74:15–23. 2014. View Article : Google Scholar :
|
|
4
|
Daniilidou K, Frangou-Plemenou M,
Grammatikakis J, Grigoriou O, Vitoratos N and Kondi-Pafiti A:
Prognostic significance and diagnostic value of PTEN and p53
expression in endometrial carcinoma. A retrospective
clinicopathological and immunohistochemical study. J BUON.
18:195–201. 2013.PubMed/NCBI
|
|
5
|
Patsner B and Yim GW: Predictive value of
preoperative serum CA-125 levels in patients with uterine cancer:
the Asian experience 2000 to 2012. Obstet Gynecol Sci. 56:281–288.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Niwa H: Molecular mechanism to maintain
stem cell renewal of ES cells. Cell Struct Funct. 26:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niwa H, Miyazaki J and Smith AG:
Quantitative expression of Oct-3/4 defines differentiation,
dedifferentiation or self-renewal of ES cells. Nat Genet.
24:372–376. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pesce M and Scholer HR: Oct-4: control of
totipotency and germline determination. Mol Reprod Dev. 55:452–457.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pesce M and Scholer HR: Oct-4: gatekeeper
in the beginnings of mammalian development. Stem Cells. 19:271–278.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan GJ, Chang ZY, Schöler HR and Pei D:
Stem cell pluripotency and transcription factor Oct4. Cell Res.
12:321–329. 2002. View Article : Google Scholar
|
|
11
|
Yu J, Vodyanik MA, Smuga-Otto K, et al:
Induced pluripotent stem cell lines derived from human somatic
cells. Science. 318:1917–1920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang YD, Cai N, Wu XL, Cao HZ, Xie LL and
Zheng PS: OCT4 promotes tumorigenesis and inhibits apoptosis of
cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis.
4:e7602013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monk M and Holding C: Human embryonic
genes re-expressed in cancer cells. Oncogene. 20:8085–8091. 2001.
View Article : Google Scholar
|
|
15
|
Suo G, Han J, Wang X, et al: Oct4
pseudogenes are transcribed in cancers. Biochem Biophys Res Commun.
337:1047–1051. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Y, Jin H, Liu Y, et al: FSH inhibits
ovarian cancer cell apoptosis by up-regulating survivin and
down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y, Liu S, Xin H, et al: Up-regulation
of microRNA-145 promotes differentiation by repressing OCT4 in
human endometrial adenocarcinoma cells. Cancer. 117:3989–3998.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu N, Papagiannakopoulos T, Pan G, Thomson
JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and
represses pluripotency in human embryonic stem cells. Cell.
137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu J, Guo H, Li H, et al: MiR-145
regulates epithelial to mesenchymal transition of breast cancer
cells by targeting Oct4. PLoS One. 7:e459652012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: the Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Petrov DA and Hartl DL: Pseudogene
evolution and natural selection for a compact genome. J Hered.
91:221–227. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirotsune S, Yoshida N, Chen A, et al: An
expressed pseudogene regulates the messenger-RNA stability of its
homologous coding gene. Nature. 423:91–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Korneev SA, Park JH and O’Shea M: Neuronal
expression of neural nitric oxide synthase (nNOS) protein is
suppressed by an antisense RNA transcribed from an NOS pseudogene.
J Neurosci. 19:7711–7720. 1999.PubMed/NCBI
|
|
25
|
Harrison PM, Zheng D, Zhang Z, Carriero N
and Gerstein M: Transcribed processed pseudogenes in the human
genome: an intermediate form of expressed retrosequence lacking
protein-coding ability. Nucleic Acids Res. 33:2374–2383. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han YJ, Ma SF, Yourek G, Park YD and
Garcia JG: A transcribed pseudogene of MYLK promotes cell
proliferation. FASEB J. 25:2305–2312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Poliseno L, Salmena L, Zhang J, Carver B,
Haveman WJ and Pandolfi PP: A coding-independent function of gene
and pseudogene mRNAs regulates tumour biology. Nature.
465:1033–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pain D, Chirn GW, Strassel C and Kemp DM:
Multiple retrop-seudogenes from pluripotent cell-specific gene
expression indicates a potential signature for novel gene
identification. J Biol Chem. 280:6265–6268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang S, Wu Y, Feng D, et al: miR-145
inhibits lung adenocarcinoma stem cells proliferation by targeting
OCT4 gene. Zhongguo Fei Ai Za Zhi. 14:317–322. 2011.(In Chinese).
PubMed/NCBI
|
|
30
|
Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY
and Cheung AN: Dysregulated stemness-related genes in gynecological
malignancies. Histol Histopathol. 27:1121–1130. 2012.PubMed/NCBI
|
|
31
|
Zhou X, Zhou YP, Huang GR, et al:
Expression of the stem cell marker, Nanog, in human endometrial
adenocarcinoma. Int J Gynecol Pathol. 30:262–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karoubi G, Gugger M, Schmid R and Dutly A:
OCT4 expression in human non-small cell lung cancer: implications
for therapeutic intervention. Interact Cardiovasc Thorac Surg.
8:393–397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang PZ, Lu CL, Li BK, et al: OCT4
expression in hepatocellular carcinoma and its clinical
significance. Chin J Cancer. 29:111–116. 2010.(In Chinese).
View Article : Google Scholar
|
|
34
|
Ezeh UI, Turek PJ, Reijo RA and Clark AT:
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are
expressed in both seminoma and breast carcinoma. Cancer.
104:2255–2265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu K, Zhu Z and Zeng F: Expression and
significance of Oct4 in bladder cancer. J Huazhong Univ Sci
Technolog Med Sci. 27:675–677. 2007. View Article : Google Scholar
|
|
36
|
Wang XQ, Ongkeko WM, Chen L, et al:
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver
cancer cells through a potential Oct4-AKT-ATP-binding cassette G2
pathway. Hepatology. 52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Z, Zhu Y, Lai Y, et al:
Follicle-stimulating hormone inhibits apoptosis in ovarian cancer
cells by regulating the OCT4 stem cell signaling pathway. Int J
Oncol. 43:1194–1204. 2013.PubMed/NCBI
|
|
38
|
Li C, Yan Y, Ji W, et al: OCT4 positively
regulates survivin expression to promote cancer cell proliferation
and leads to poor prognosis in esophageal squamous cell carcinoma.
PLoS One. 7:e496932012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dai X, Ge J, Wang X, Qian X, Zhang C and
Li X: OCT4 regulates epithelial-mesenchymal transition and its
knockdown inhibits colorectal cancer cell migration and invasion.
Oncol Rep. 29:155–160. 2013.
|
|
40
|
Pei D: Regulation of pluripotency and
reprogramming by transcription factors. J Biol Chem. 284:3365–3369.
2009. View Article : Google Scholar
|
|
41
|
Slaby O, Svoboda M, Fabian P, et al:
Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer.
Oncology. 72:397–402. 2007. View Article : Google Scholar
|
|
42
|
Tam OH, Aravin AA, Stein P, et al:
Pseudogene-derived small interfering RNAs regulate gene expression
in mouse oocytes. Nature. 453:534–538. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ebert MS, Neilson JR and Sharp PA:
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian
cells. Nat Methods. 4:721–726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang L, Guo ZY, Zhang R, Xin B, Chen R,
Zhao J, Wang T, Wen WH, Jia LT, Yao LB and Yang AG: Pseudogene
OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4
expression by competing for miR-145 in hepatocellular carcinoma.
Carcinogenesis. 34:1773–1781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu T, Liu S, Breiter DR, Wang F, Tang Y
and Sun S: Octamer 4 small interfering RNA results in cancer stem
cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008.
View Article : Google Scholar : PubMed/NCBI
|
